242 related articles for article (PubMed ID: 31597836)
1. [Treatment of higher risk myelodysplastic syndromes].
Usuki K
Rinsho Ketsueki; 2019; 60(9):1131-1139. PubMed ID: 31597836
[TBL] [Abstract][Full Text] [Related]
2. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
Steensma DP
Best Pract Res Clin Haematol; 2012 Dec; 25(4):443-51. PubMed ID: 23200541
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
4. Optimal sequencing of treatments for patients with myelodysplastic syndromes.
Itzykson R; Fenaux P
Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268
[TBL] [Abstract][Full Text] [Related]
5. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant.
Bewersdorf JP; Stahl M; Zeidan AM
Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770
[TBL] [Abstract][Full Text] [Related]
6. Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome.
Falconi G; Fabiani E; Criscuolo M; Fianchi L; Finelli C; Cerqui E; Pelosi E; Screnci M; Gurnari C; Zangrilli I; Postorino M; Laurenti L; Piciocchi A; Testa U; Lo-Coco F; Voso MT
Leuk Res; 2019 Sep; 84():106191. PubMed ID: 31386932
[TBL] [Abstract][Full Text] [Related]
7. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Flotho C; Sommer S; Lübbert M
Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
[TBL] [Abstract][Full Text] [Related]
9. Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome.
Nishihori T; Perkins J; Mishra A; Komrokji R; Kim J; Kharfan-Dabaja MA; Perez L; Lancet J; Fernandez H; List A; Anasetti C; Field T
Biol Blood Marrow Transplant; 2014 Jun; 20(6):776-80. PubMed ID: 24534108
[TBL] [Abstract][Full Text] [Related]
10. Myelodysplastic syndromes: therapy and outlook.
Lyons RM
Am J Med; 2012 Jul; 125(7 Suppl):S18-23. PubMed ID: 22735747
[TBL] [Abstract][Full Text] [Related]
11. Transplants in myelodysplastic syndromes.
Wetzko K; Platzbecker U
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1011-22. PubMed ID: 25459176
[TBL] [Abstract][Full Text] [Related]
12. Evolving treatment options of myelodysplastic syndromes.
Verbeek W; Ganser A
Ann Hematol; 2001 Sep; 80(9):499-509. PubMed ID: 11669297
[TBL] [Abstract][Full Text] [Related]
13. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation.
Field T; Perkins J; Huang Y; Kharfan-Dabaja MA; Alsina M; Ayala E; Fernandez HF; Janssen W; Lancet J; Perez L; Sullivan D; List A; Anasetti C
Bone Marrow Transplant; 2010 Feb; 45(2):255-60. PubMed ID: 19543327
[TBL] [Abstract][Full Text] [Related]
14. Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies.
Maples KT; Sabo RT; McCarty JM; Toor AA; Hawks KG
Leuk Lymphoma; 2018 Dec; 59(12):2836-2841. PubMed ID: 29616863
[TBL] [Abstract][Full Text] [Related]
15. [Management of patients with higher-risk myelodysplastic syndromes].
Morita Y
Rinsho Ketsueki; 2020; 61(9):1218-1226. PubMed ID: 33162519
[TBL] [Abstract][Full Text] [Related]
16. First-line Therapeutic Strategies for Myelodysplastic Syndromes.
Santini V
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S31-S36. PubMed ID: 28760300
[TBL] [Abstract][Full Text] [Related]
17. Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome.
Park S; Baek DW; Sohn SK; Ahn JS; Kim HJ; Shin HJ; Chung JS; Lee SM; Lee WS; Lim SN; Lee YJ; Choi Y; Lee HS; Cho YY; Lee GW; Moon JH
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e367-e373. PubMed ID: 31060990
[TBL] [Abstract][Full Text] [Related]
18. Impact of prior azacitidine on the outcome of allogeneic hematopoietic transplantation for myelodysplastic syndrome.
Oshikawa G; Yoshioka K; Takahashi Y; Shingai N; Ikegawa S; Kobayashil T; Doki N; Kakihana K; Ohashi K; Sakamaki H
Pathol Oncol Res; 2015 Sep; 21(4):1037-43. PubMed ID: 25837848
[TBL] [Abstract][Full Text] [Related]
19. Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation.
Waespe N; Van Den Akker M; Klaassen RJ; Lieberman L; Irwin MS; Ali SS; Abdelhaleem M; Zlateska B; Liebman M; Cada M; Schechter T; Dror Y
Haematologica; 2016 Dec; 101(12):1508-1515. PubMed ID: 27540140
[TBL] [Abstract][Full Text] [Related]
20. Pretransplantation therapy with hypomethylating agents in patients with myelodysplastic syndromes receiving reduced-intensity conditioning regimens.
Della Porta MG; Alessandrino EP
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1260-1. PubMed ID: 25020100
[No Abstract] [Full Text] [Related]
[Next] [New Search]